Journal
JOURNAL OF CLINICAL PSYCHIATRY
Volume 63, Issue 11, Pages 1028-1033Publisher
PHYSICIANS POSTGRADUATE PRESS
DOI: 10.4088/JCP.v63n1113
Keywords
-
Categories
Ask authors/readers for more resources
Background: The purpose of this study was to assess the efficacy and safety of fluoxetine in the treatment of binge-eating disorder. Method: Sixty outpatients with a DSM-IV diagnosis of binge-eating disorder were randomly assigned to receive either fluoxetine, 20 to 80 mg/day (N = 30), or placebo (N = 30) in a 6-week, double-blind, flexible-dose study. The primary measure of efficacy was frequency of binge eating. Secondary measures included body mass index, weight, Clinical Global Impressions-Severity of Illness score, Hamilton Rating Scale for Depression (HAM-D) score, and response categories. The outcome measures were analyzed using 2 random regression methods, a time trend analysis (primary analysis) and an endpoint analysis. In addition, response categories were analyzed using an exact trend test. Results: Compared with placebo-treated subjects, subjects receiving fluoxetine (mean +/- SD endpoint dose = 71.3 +/- 11.4 mg/day) had a significantly greater reduction in frequency of binge eating (p = .033), body mass index (p < .0001), weight (p = .001), and severity of illness (p = .032) and a marginally significant reduction in HAM-D scores (p = .061). Differences between groups on response categories were not statistically significant. Conclusion: In a 6-week, placebo-controlled, flexible-dose trial, fluoxetine was efficacious in reducing binge-eating frequency, weight, and severity of illness and was generally well tolerated in subjects with binge-eating disorder.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available